Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy
- PMID: 17721591
- DOI: 10.1039/b708320c
Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy
Abstract
We report the synthesis, spectroscopic properties and intracellular imaging of recombinant antibody single chain fragment (scFv) conjugates with photosensitizers used for photodynamic therapy of cancer (PDT). Two widely-studied photosensitizers have been selected: preclinical pyropheophorbide-a (PPa) and verteporfin (VP), which has been clinically approved for the treatment of acute macular degeneration (Visudyne). Pyropheophorbide-a and verteporfin have been conjugated to an anti-HER2 scFv containing on average ten photosensitizer molecules per scFv with a small contribution (<or=20%) from non-covalently bound molecules. Confocal fluorescence microscopy demonstrates good cellular uptake of PPa conjugate with the HER2-positive cell line, SKOV-3, while negligible cell uptake is demonstrated for the HER2-negative cell line, KB. For the VP conjugate, increased rate of cellular uptake and prolonged retention in SKOV-3 cells is observed compared to free photosensitizer. In clinical applications this could provide increased potency and desired selectivity towards malignant tissue, leaving surrounding healthy tissue unharmed and reducing skin photosensitivity. The present study highlights the usefulness of photosensitizer immunoconjugates with scFvs for targeted PDT.
Similar articles
-
Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.Cancer Res. 2005 Jul 15;65(14):6371-9. doi: 10.1158/0008-5472.CAN-05-0426. Cancer Res. 2005. PMID: 16024640
-
Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy.Bioorg Med Chem. 2005 Apr 15;13(8):2799-808. doi: 10.1016/j.bmc.2005.02.025. Bioorg Med Chem. 2005. PMID: 15781391
-
Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments.Int J Cancer. 2008 Mar 1;122(5):1155-63. doi: 10.1002/ijc.23206. Int J Cancer. 2008. PMID: 17973256
-
Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT.J Photochem Photobiol B. 2009 Jul 17;96(1):1-8. doi: 10.1016/j.jphotobiol.2009.04.001. Epub 2009 Apr 11. J Photochem Photobiol B. 2009. PMID: 19406659 Review.
-
Endobronchial photodynamic therapy for lung cancer.Lasers Surg Med. 2006 Jun;38(5):364-70. doi: 10.1002/lsm.20354. Lasers Surg Med. 2006. PMID: 16788932 Review.
Cited by
-
A lifetime in photochemistry; some ultrafast measurements on singlet states.Proc Math Phys Eng Sci. 2016 Jun;472(2190):20160102. doi: 10.1098/rspa.2016.0102. Proc Math Phys Eng Sci. 2016. PMID: 27436979 Free PMC article. Review.
-
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.Br J Cancer. 2011 Mar 29;104(7):1106-15. doi: 10.1038/bjc.2011.78. Epub 2011 Mar 8. Br J Cancer. 2011. PMID: 21386847 Free PMC article.
-
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate.Antib Ther. 2024 Feb 16;7(2):114-122. doi: 10.1093/abt/tbae005. eCollection 2024 Apr. Antib Ther. 2024. PMID: 38566971 Free PMC article. Review.
-
The Mechanism of Fluorescence Quenching of Protein Photosensitizers Based on miniSOG During Internalization of the HER2 Receptor.Acta Naturae. 2018 Oct-Dec;10(4):87-94. Acta Naturae. 2018. PMID: 30713766 Free PMC article.
-
Use of photoimmunoconjugates to characterize ABCB1 in cancer cells.Nanophotonics. 2021 Sep;10(12):3049-3061. doi: 10.1515/nanoph-2021-0252. Epub 2021 Jul 26. Nanophotonics. 2021. PMID: 35070633 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
